156 related articles for article (PubMed ID: 38488892)
1. The impact of the relationship between lesion diameter and total core length on the detection rate of clinically significant prostate cancer for PI-RADS 3 lesions.
Yakut E
World J Urol; 2024 Mar; 42(1):162. PubMed ID: 38488892
[TBL] [Abstract][Full Text] [Related]
2. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
4. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
5. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
Yilmaz EC; Shih JH; Belue MJ; Harmon SA; Phelps TE; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
Radiology; 2023 May; 307(4):e221309. PubMed ID: 37129493
[TBL] [Abstract][Full Text] [Related]
6. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
[TBL] [Abstract][Full Text] [Related]
7. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591
[TBL] [Abstract][Full Text] [Related]
8. A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI.
Hou Y; Jiang KW; Zhang J; Bao ML; Shi HB; Qu JR; Cheng G; Zhang YD
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):727-734. PubMed ID: 35067674
[TBL] [Abstract][Full Text] [Related]
9. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
10. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
Mazzone E; Stabile A; Pellegrino F; Basile G; Cignoli D; Cirulli GO; Sorce G; Barletta F; Scuderi S; Bravi CA; Cucchiara V; Fossati N; Gandaglia G; Montorsi F; Briganti A
Eur Urol Oncol; 2021 Oct; 4(5):697-713. PubMed ID: 33358543
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5].
Liu Y; Yuan CW; Wu JY; Shen Q; Xiao JX; Zhao Z; Wang XY; Li XS; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):812-817. PubMed ID: 37807733
[TBL] [Abstract][Full Text] [Related]
12. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
[TBL] [Abstract][Full Text] [Related]
13. Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort.
Chaloupka M; Pyrgidis N; Ebner B; Volz Y; Pfitzinger PL; Berg E; Enzinger B; Atzler M; Ivanova T; Clevert DA; Buchner A; Stief CG; Apfelbeck M
BJU Int; 2024 May; 133(5):548-554. PubMed ID: 38060339
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
[TBL] [Abstract][Full Text] [Related]
15. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
[TBL] [Abstract][Full Text] [Related]
16. Combination of Multiparametric Magnetic Resonance Imaging With Elastic-fusion Biopsy Has a High Sensitivity in Detecting Clinically Significant Prostate Cancer in Daily Practice.
Cecchini S; Castellani D; Fabbietti P; Mazzucchelli R; Montironi R; Cecarini M; Carnevali F; Pierangeli T; Dellabella M; Ravasi E
Clin Genitourin Cancer; 2020 Oct; 18(5):e501-e509. PubMed ID: 32147365
[TBL] [Abstract][Full Text] [Related]
17. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
18. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of core number and location.
Martin R; Belahsen Y; Noujeim JP; Lefebvre Y; Lemort M; Deforche M; Sirtaine N; Roumeguere T; Albisinni S; Peltier A; Diamand R
World J Urol; 2023 Jun; 41(6):1519-1525. PubMed ID: 37010577
[TBL] [Abstract][Full Text] [Related]
19. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
20. Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series.
Pellegrino F; Stabile A; Mazzone E; Sorce G; Barletta F; De Angelis M; Brembilla G; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Prostate; 2022 Sep; 82(12):1170-1175. PubMed ID: 35538401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
